Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Journey Medical's pretax income for the
three
months ended in Jun. 2026 was $-0.30 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-6.09 Mil.
Journey Medical's pretax margin was -1.60%.
During the past 7 years, Journey Medical's highest Pretax Margin was 16.06%. The lowest was -67.10%. And the median was -18.38%.
During the past 7 years, Journey Medical's highest Pretax Margin was 16.06%. The lowest was -67.10%. And the median was -18.38%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical Pre-Tax Income Related Terms
Journey Medical Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Journey Medical's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DERM vs SIGA, ORGO, AKBA: Pre-Tax Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Journey Medical's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical (DERM) has a Pre-Tax Income of $-6.09 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Journey Medical and its competitors.
Is Journey Medical's Pre-Tax Income too high?
Journey Medical's current Pre-Tax Income is $-6.09 Mil. Overall, Journey Medical has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Pre-Tax Income compare to SIGA and ORGO?
Journey Medical's Pre-Tax Income of $-6.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Journey Medical and its competitors. Journey Medical's current Pre-Tax Income is $-6.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.12, compared to a current price of $7.86 — trading 53.5% above its estimated fair value. The current Pre-Tax Income is $-6.09 Mil. Journey Medical's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Journey Medical (DERM), the current Pre-Tax Income is $-6.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $7.86 is trading 53.5% above its estimated GF Value™ of $5.12.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
Pre-Tax Income: $-6.09 Mil
GF Value™: $5.12 vs. price of $7.86 (53.5% above fair value)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
61GF Score
Get the complete analysis for DERM
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
